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MIF-1 (Pro-Leu-Gly-NH2) is a tripeptide for which the therapeutic potential in Parkinson’s disease and depression has been
indicated by many studies. However, the cellular mechanisms of action of MIF-1 are not yet clear. Here, we show the speciﬁc brain
regions responsive to MIF-1 treatment by c-Fos mapping, and determine the kinetics of cellular signaling by western blotting
of pERK, pSTAT3, and c-Fos in cultured neurons. The immunoreactivity of c-Fos was increased 4 hours after MIF-1 treatment
in brain regions critically involved in the regulation of mood, anxiety, depression, and memory. The number of cells activated
was greater after peripheral treatment (intravenous delivery) than after intracerebroventricular injection. In cultured SH-SY5Y
neuronalcells,c-Foswasinducedtime-anddose-dependently.Theactivationofcellular c-Foswasprecededbyatransientincrease
of mitogen-activated protein kinase pERK but a reduction of phosphorylated Signal Transducer and Activator of Transcription
(pSTAT3) initially. We conclude that MIF-1 can modulate multiple cellular signals including pERK, and pSTAT3 to activate c-Fos.
The cellular activation in speciﬁc brain regions illustrates the biochemical and neuroanatomical basis underlying the therapeutic
eﬀect of MIF-1 in Parkinson’s disease and depression.
1.Introduction
Melanocyte-stimulating hormone release inhibiting factor-1
(MIF-1), also known as PLG based on its amino acid struc-
ture (Pro-Leu-Gly-NH2), is an endogenous brain peptide
that exerts a variety of pharmacological eﬀects on the central
nervous system [1]. Clinical studies have shown that MIF-
1 can alleviate symptoms in Parkinson’s disease (PD) and
mental depression. These have been summarized elsewhere,
although the review overlooked a report in the Chinese
literature of favorable results of MIF-1 in PD [2]. MIF-1
was the ﬁrst hypothalamic peptide shown to act “up” on the
brain,notjust“down”onthepituitary[3].Inhumanplasma,
a duration of 5 days is required for 50% degradation of MIF-
1a t3 7
◦C[ 4]. This remarkable stability of MIF-1 in human
blood, coupled with its persisting biological activity, makes
MIF-1 a worthwhile candidate as a human therapeutic agent.
The therapeutic potential of MIF-1 indicates the impor-
tance of further determining how it acts on the brain.
There already is evidence that MIF-1 activates CNS pathways
related to opiate and dopaminergic systems based on the
following evidence: (1) MIF-1 antagonizes opiate actions,
and the ﬁrst report of such activity correctly predicted the
discovery of other endogenous antiopiate peptides blocking
the analgesic eﬀect of morphine and enkephalin in a
radiant heat tail-ﬂick assay [5]. MIF-1 also signiﬁcantly
antagonized the eﬀects of morphine in a double-blind
study in humans [6]. (2) MIF-1 is eﬀective in the DOPA-
potentiation, oxotremorine antagonism, and deserpidine
antagonism tests [7]. In a small number of patients with PD,
Barbeau [8] found its potentiation of the eﬀects of levodopa
to be remarkable; (3) MIF-1 can modulate dopaminergic
transmission in-vitro as well as in-vivo, increasing the
binding aﬃnity of agonists to the high-aﬃnity state of the
dopamine receptor and shifting the ratio of high- and low-
aﬃnity states of the dopamine receptor in favor of the G-
protein-coupled high-aﬃnity state [9]. (4) The actions of
MIF-1 appear rather selective toward dopamine receptors
since it does not interact with other aminergic receptors
such as adrenergic [9], GABAergic [10], or serotonergic
receptors [11]. (5) MIF-1 also facilitates passive acquisition
of brightness discrimination, passive avoidance retention,2 International Journal of Peptides
appetitive maze performance, and inhibits shock-suppressed
water intake, ﬁndings interpreted as contributing to the
processes of memory consolidation [1, 12]. However, MIF-1
doesnotchangecAMPinthebrainincontrasttotheincrease
induced by α-MSH, and its induction of cGMP is not robust
in rat brain [13]. This led us to study alternative cellular
signaling pathways.
A number of exogenous stimuli, including an increase in
neuronal activity, trigger the transcription of c-Fos, which
is an immediate early gene that in combination with the
speciﬁc Jun proteins forms the heterodimeric transcrip-
tion regulator, AP-1 [14]. The extracellular signal-regulated
kinase (ERK)-1/2 pathways are involved in the induction
and regulation of c-Fos [15] .I nt h i ss t u d y ,w ep e r f o r m e d
a brain mapping of the neuronal expression of c-Fos after
intravenous (iv) or intracerebroventricular (icv) injection of
MIF-1. We also determined the upstream signaling pathways
leading to the activation.
2.MaterialsandMethods
2.1. Animals and Reagents. All studies were conducted
following a protocol approved by the Institutional Animal
Care and Use Committee. Adult male C57BL/6J mice were
purchased from Jackson Laboratories (Bar Harbor, ME) and
housed in the animal care facility for at least 2 weeks before
study. The mice were housed 4/cage and provided with
regularrodentchowandwateradlibitum.Theambientroom
temperaturewas23
◦C.Thelight span was07:00–19:00 hours
in a light-dark (LD) 12:12 lighting regimen.
MIF-1 was purchased from Phoenix pharmaceuticals
(Burlingame, CA) and reconstituted in phosphate-buﬀered
saline (PBS) before use. Rabbit polyclonal anti-c-Fos anti-
body, goat anti-pSTAT3-Tyr705 antibody, and mouse anti-
pERK E-4 monoclonal antibody were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-rat NeuN anti-
body was purchased from Chemicon (Billerica, MA). Anti-
β-actin antibody and other chemicals were obtained from
S i g m a( S t .L o u i s ,M O ) .
2.2. Immunoﬂuorescent Staining. In accordance with a pro-
tocol approved by the Institutional Animal Care and Use
Committee, C57BL/6J male mice (5–7 weeks old) were
anesthetized by intramuscular injection of ketamine and
xylazine. MIF-1 was delivered either into the isolated left
jugular vein (iv) at 10μg/mouse in a volume of 50μL
(n = 3), or into the right lateral cerebral ventricle (icv)
at 1μg/mouse in a volume of 1μL( n = 3). The control
groups received the same volume of PBS (n = 3). The icv
coordinates were 2mm lateral and 0.2mm posterior to the
bregma,and2.5mmbelowtheskull.Themicewereperfused
intracardially with 30mL of normal saline (NS) followed
by 60mL of 4% paraformaldehyde. The brain was postﬁxed
overnight in 4% paraformaldehyde and cryoprotected in
15% and then 30% sucrose. Coronal sections of 20μm
thickness were obtained by the use of a cryostat. The tissue
sections were permeabilized with 0.3% Triton X-100 and
blockedwith10%normaldonkeyserum,andincubatedwith
a primary antibody overnight at 4◦C. The antibodies include
rabbit polyclonal anti-c-Fos antibody (1 : 200, Santa Cruz
Biotechnology sc-52) and anti-rat NeuN antibody (1 : 100,
Chemicon). After thorough washing, they were incubated
with respective Alexa488-conjugated secondary antibodies
at room temperature for 1 hour, washed, and mounted.
Negative controls were incubated with a secondary antibody
only.
2.3. Cell Culture and Western Blotting. SH-SY5Y human
neuroblastoma cells (American Type Culture Collection,
ATCC, Manassas, VA) were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS). The cells were diﬀerentiated by treatment with 10μM
of all-trans retinoic acid (Sigma, St. Louis, MO, USA)
between 1 and 6 days after plating. Sixteen hours after
serum starvation, the cells were treated with MIF-1 (1–
10ng/mL for diﬀerent time intervals (0–3 hours). All cells
were plated at the same time and treated according to the
time intervals designed for individual experiments. The cells
were lysed in ice-cold RIPA buﬀer (100mM NaCl, 10 mM
Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate,
5mM EDTA) in the presence of protease inhibitor cocktail
(Pierce,Rockford,IL).Thelysatesweresonicatedandcleared
by ultracentrifugation. The protein content was measured
by bicinchoninic acid assay (Pierce). Thirty to 50μgo f
protein was electrophoresed on 12% SDS-polyacrylamide
gel and transferred to a nitrocellulose membrane (Bio-Rad,
Hercules, CA). The membrane was blocked with 5% non-
fat dry milk in Tris-buﬀered saline (pH 7.6) containing 0.1%
Tween-20, and probed with rabbit anti-c-Fos (polyclonal,
1 : 200, Santa Cruz Biotechnology, sc-52), goat anti-pSTAT3
Tyr 705 (polyclonal, 1 : 1,000 sc-7993), mouse anti-pERK
E-4 (monoclonal, 1 : 500, sc-7383 and mouse anti-β-actin
(monoclonal, 1 : 10,000, Sigma, A2228) overnight at 4◦C.
After thorough washing, the membranes were incubated
with horseradish peroxidase-conjugated secondary antibody
for 1 hour at room temperature. The signals were developed
with enhanced chemiluminescence-plus western blotting
detection reagents (Amersham Biosciences, Piscataway, NJ).
3. Results
3.1. MIF-1 Increases c-Fos Expression in Speciﬁc Diﬀerent
Brain Regions. We previously observed that MIF-1 is sat-
urably transported from blood to brain [16]. In this study,
we demonstrate that iv injection of MIF-1 increased c-Fos
immunoreactivity in diﬀerent brain regions. The regions
that showed the highest c-Fos activation include cingulate
cortex (Figures 1(c3) and 2(a)), infralimbic cortex (Figures
1(c1) and 2(e)), nucleus accumbens (Figures 1(c1) and 2(i)),
paraventricularnucleus(PVN)inthehypothalamus(Figures
1(c5) and 2(f)), medial basal amygdaloid nucleus (Figures
1(c6) and 2(h)), ﬁber tract in piriform cortex (Figures 1(c6)
and 2(g)), paraventricular thalamic nucleus (Figures 1(c6),
2(c),a n d2(d)), and other thalamic nuclei (Figures 1(c7)
and 2(b)). Double labeling with NeuN showed that many
of the cells expressing c-Fos were neurons. The increase inInternational Journal of Peptides 3
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Figure 1:MappingofMIF-1-inducedbrainactivationofc-Fosimmunoreactivityandicvandivadministration.Verticalpanel(a)represents
the control brain, panel (b) represents c-Fos immunoreactivity 4 hours after icv injection of MIF-1 (1μg/mouse), and panel (c) represents
c-Fos immunoreactivity 4 hours after iv injection of MIF-1 (10μg/mouse). Horizontal rows 1–7 represent various sections of the brain from
the anterior to the posterior part of the brain. The distances from interaural and bregma in mm are 1: 5.58 and 1.78, 2: 4.54 and 0.74, 3: 4.06
and 0.26, 4: 3.46 and −0.34, 5: 5.58 and 1.78, 6: 2.34 and −1.46, 7: 1.10 and −2.70.
c-Fos expression was greater after iv injection than after icv
injection in many brain regions. This is consistent with the
abilityofstablesubstancesinthecerebralcirculationtoreach
all parts of the brain rapidly. After icv, the increase of c-
Fos was mainly seen in the paraventricular nucleus of the
hypothalamus (Figures 1(b5) and 2(f)). The basal level of
activation of PBS icv and iv was similar. Thus, only the icv-
injected controls are shown in Figure 2. Table 1 summarizes
the number of c-Fos immunopositive cells in diﬀerent brain
regions.
3.2. MIF-1 Increases c-Fos Expression in Cultured Neurons.
Western blotting showed that the c-Fos signal was increased
60 minutes after MIF-1 treatment (10ng/mL). This per-
sisted at 2 and 3 hours (Figure 3(a)). There was also a
dose-dependent increase, highest at the maximal dose ofInternational Journal of Peptides 5
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Figure 2: Detailed immunohistochemical representation of MIF-1 induced brain activation by c-Fos immunoreactivity. The panels on
the left show basal c-Fos activity in diﬀerent regions. The second panels show c-Fos immunoreactivity 4 hours after iv injection of MIF-1
(10μg/mouse).Thethirdpanels showc-Fos immunoreactivity 4hours after icv injection ofMIF-1(1μg/mouse).Thelastpanels show NeuN
(+) neurons (red), DAPI-labeled nucleus (blue), as well as c-Fos (green) in sections after iv injection. (a) Cingulate cortex, (b) Thalamic
nucleus, (c) Paraventricular thalamic nucleus, anterior part, (d) Paraventricular thalamic nucleus, posterior part, (e) Infralimbic cortex, (f)
Paraventricular nucleus of the hypothalamus, (g) medial amygdaloid nucleus, (h) Fiber tract in piriform cortex, and (i) Nucleus accumbens.
Table 1: Relative numbers of c-Fos (+) cells after MIF-1 treatment.
Structure abbreviation Figure 1 diagram Structure Saline icv iv
cg1 (1)(a)–(c) Cingulate cortex, area1 +a +a +++++ c
cg2 (2)(a)–(c) Cingulate cortex, area2 +a +a ++++ d
IL (1)(a)–(c) Infralimbic cortex + o ++b
DEn (1)(a)–(c) Dorsal endopiriform cortex ++ +b ++ +++d
CPu (1)(a)–(c) Caudate, putamen + o ++d
AcbC (1)(a)–(c) Accumbens nucleus, core + + ++ ++ +d
Pir (3)(a)–(c) Piriform cortex ++b ++b +++ b
PaDC (5)(a)–(c) Paraventricular hypothalamic nucleus, dorsal cap +++ +++ ++ ++ +d
PaLM (5)(a)–(c) Paraventricular hypothalamic nucleus, lateral magnocellular +++ +++ +++++d
PV (6)(a)–(c) Paraventricular thalamic nu +++ + ++ ++ +d
PCom (7)(a)–(c) Nucleus of posterior commissure ++b ++ + b
MCPC (7)(a)–(c) Magnocellular nucleus of posterior commissure + o ++b
RPF (7)(a)–(c) Retroparafascicular nucleus o + ++b
PAG (7)(a)–(c) Periaqueductal gray + ++d ++b +++++ d
IMD (6)(a)–(c) Intermed-dorsal thalamic nucleus + ++d ++b +++++ d
BMA (6)(a)–(c) Basomedial amygdaloid nucleus, anterior + ++b +++ c
o: absent immunoreactivity; +: low immunoreactivity; ++: modest immunoreactivity; +++: moderate immunoreactivity; ++++: dense immunoreactivity;
+++++: very dense immunoreactivity. a: punctate immunoreactivity; b: sparse immunoreactivity; c: variable density; d: cluster of dense immunoreactivity.International Journal of Peptides 7
MIF-1 (10ng/mL)
Time (min) 0 10 60 120 180
c-Fos
β-actin
(a)
MIF-1
(ng/mL) 0 6.25 12.5 25 50 100
c-Fos
β-actin
MIF-1
(μg/mL) 0 0.10 .51 5 1 0
c-Fos
β-actin
(b)
Figure 3: MIF-1 activates cultured SH-SY5Y neurons, shown by
western blotting of c-Fos. (a) MIF-1 increased neuronal c-Fos at 1,
2, and 3 hours at a concentration of 10ng/mL, showing its time-
dependent pattern. (b) MIF-1 increased c-Fos at all concentrations
tested at 1 hour, showing its dose-response.
MIF-1 (10ng/mL)
Time (min) 0 10 60 120 180
pERK 1/2
β-actin
Figure 4: MIF-1 (10ng/mL) induced a time-dependent increase of
pERK1 (44kD) and pERK2 (42kD), most apparent at 10 minutes.
10μg/mL, but even the lowest concentration of MIF-1 tested
(6.25ng/mL)showedarobustinductionofc-Fos1hourlater
(Figure 3(b)).
3.3. MIF-1 Induces a Transient Increase of pERK but Causes
a Biphasic Change of pSTAT3. Western blotting analysis
showedthatpERKexpressionwasincreasedinSH-SY5Ycells
10 minutes after MIF-1 treatment (10ng/mL) (Figure 4).
By contrast, the cells responded to MIF-1 with an initial
r e d u c t i o no fp S T A T 3a t1 0a n d6 0m i n u t e s ,f o l l o w e db y
increased pSTAT3 expression at 2 and 3 hours (Figure 5).
4. Discussion
In this study, we showed that MIF-1 induces c-Fos activation
in diﬀerent regions of the brain and in cultured neurons.
MIF-1 also induced c-Fos in non-NeuN (+) cells. This is the
MIF-1 (10ng/mL)
Time (min) 0 10 60 120 180
pSTAT3(705)
β-actin
Figure 5: MIF-1 (10ng/mL) induced a time-dependent change of
pSTAT3-Y705, shown by an initial decrease at 10 and 60 minutes,
and a subsequent increase at 2 and 3 hours.
ﬁrst report stating that MIF-1 increases the phosphorylation
of ERK, indicative of activation of a mitogen-activated
protein kinase (MAPK) pathway. Our results show that MIF-
1 decreased pSTAT3 initially (10 and 60 minutes), but then
increased pSTAT3 at later times (2 and 3 hours) in neuronal
culture, probably reﬂecting a secondary mechanism. This
alsoistheﬁrstreportshowingthatMIF-1modulatespSTAT3
activation, although the functional consequences are not
clear. These are not classical elements of the GPCR signaling
pathway, and suggest a broader action of this orphan ligand.
While a peptide like MIF-1 may either show direct CNS
eﬀects or activate secondary mediators, c-Fos immunoreac-
tivity reﬂects a ﬁnal common pathway of brain activation
as a result of MIF-1 application. The immediate early gene
product c-Fos is an easily identiﬁable and rather sensitive
marker for CNS activation. The increase of c-Fos has
been demonstrated after various stimuli, including growth
factors, ion channel activation, neurotransmitter release, and
behavioral modiﬁcations [17]. The increase of its expression
can be mediated by many intracellular signaling pathways,
such as increases in cAMP, calcium inﬂux, and activation
of MAPK [18]. Our results show that the increase in c-Fos
expression is greater after iv injection than after icv injection
in many brain regions. After icv administration, the increase
of c-Fos immunoreactivity was mainly seen in the PVN of
the hypothalamus. Considering that less than 1% of MIF-
1 from blood permeates the blood-brain barrier to reach
the brain, like most centrally active peptides and even L-
DOPA and morphine, this indicates that blood-borne MIF-
1i sm o r ee ﬀective than when administered into the slower
movingventricularsystemofthebrain.Thisisnotsurprising
considering that no neuron is more than about 8μmf r o m
a capillary [19]. It is also possible that peripherally injected
MIF-1 activates additional mediators, thus triggering a
cascade of signalling events. The implications of MIF-
1-induced c-Fos activation in diﬀerent brain regions are
discussed below.
(1) Cingulate cortex: the cingulate cortex is an anatomi-
callyandfunctionallyheterogeneousregionanditmodulates
emotion and mood. Attention deﬁcit in PD has been
explained by dopamine depletion of the cingulate cortex
[20]. Fornix-induced lesions can reduce c-Fos immunore-
activity in the cingulate cortex of rats [21]. Earlier studies
showed that lesions of the cingulate cortex aﬀect behavior
in the open-ﬁeld and interspecies aggression behavior in
rats [22]. Melatonin (5-methoxy-N-acetyltryptamine) was8 International Journal of Peptides
reported to be critically involved in the regulation of both
mood and pain [23]. Melatonin receptor type 1 (MT1)-
knockout mice display depression-like behavior with altered
sensory responses and attention deﬁcits [24]. These previous
studies show that the central melatoninergic system might
play an important role in the mechanism of interactions
between pain and depression, and the anterior cingulate
cortex could be a forebrain region of interest in this process.
MIF-1 can potentiate the melanocyte-lightening eﬀect of
melatonin in rats [25], and its eﬀects in patients with
PD are associated with marked mood elevation. Therefore,
the MIF-1-induced c-Fos activation in the cingulate cortex
supports the speculation that the eﬀectiveness of MIF-1
in treating movement disorders may be associated with
increased melatonin secretion.
(2) Thalamus: the lateral geniculate nucleus of the
thalamus is involved in ﬂuctuations in both visual attention
and visual awareness [26]. MIF-1 can facilitate acquisition of
brightness discrimination, probably by aﬀecting processes of
attentionwhenratsaretestedwithaspatialextradimensional
shift problem after acquisition of a visual task [27]. c-Fos
expression has been found in the medial geniculate body
(MGB) of the thalamus after mice acquired a visually cued
conditioned fear. The activation of c-Fos by MIF-1 in the
thalamus supports the direct eﬀects of MIF-1 there.
(3)Infralimbiccortex:theinfralimbiccortex(IL)isacor-
tical region in the medial prefrontal cortex that is important
in tonic inhibition of subcortical structures and emotional
responses such as fear [28]. Electrical stimulation of the IL
reduces conditioned fear and strengthens extinction mem-
ory.Thisillustratescorticalcontroloverextinctionprocesses,
which is one of the simplest forms of emotional regulation
[29]. Less c-Fos immunoreactivity is present in the IL of the
extinction-resistant mouse compared with the control [30].
In a 12-choice Warden maze for a palatable food reward, rats
receiving MIF-1 have shorter latencies and make fewer errors
than controls during learning, but not extinction, of the task
[31]. Our results provide the ﬁrst direct evidence that MIF-1
can activate IL neurons.
(4) Nucleus accumbens: both typical and atypical
antipsychotic drugs increase c-Fos protein expression in
the nucleus accumbens shell [32]. The ability of MIF-1
to increase c-Fos in the forebrain may have considerable
predictive validity for antipsychotic drug actions. Admin-
istration of MIF-1 to patients with depression showed
substantial improvement within a few days after initiation
of treatment [33–35]. Previous studies showed that antipsy-
chotic drugs like clozapine and amperozide preferentially
increase dopamine release in the rat nucleus accumbens and
prefrontal cortex [36]. Hippocampal dopamine receptors
modulate c-Fos expression in the rat nucleus accumbens
that is evoked by chemical stimulation of the ventral
hippocampus [37]. Thus, MIF-1 may activate cells in the
nucleus accumbens and modulate dopaminergic activity
there to alleviate mood and schizoaﬀective disorder.
(5) PVN: the PVN plays important roles in neu-
roendocrine and autonomic nervous system controls. For
example, many experimental challenges (such as restraint
stress, dehydration, and immune challenge) induce c-Fos
expression in the PVN [38, 39]. Although MIF-1 has no
eﬀects on a naloxone-sensitive peptide YY (PYY) model
of hyperphagia after PYY injection into the PVN [40],
the induction of c-Fos by MIF-1 through both iv and icv
injectionindicatesthatPVNisamajorsiteofactionforMIF-
1.
(6) Medial amygdaloid nucleus: an avoidance task in
the elevated T maze can increase Fos protein expression in
the medial amygdaloid nucleus. The amygdala is a point
of convergence for conditioned and unconditioned stimuli
and seems to impart emotional value to sensory stimulation
[41]. Increased expression of immediate early genes in
the amygdala has been reported in several paradigms of
aversive conditioning [42]. These ﬁndings may provide a
physiological basis for MIF-1 induced c-Fos activation in the
amygdala.
(7) Piriform cortex: the presence of the c-Fos protein has
been shown in the piriform cortex at diﬀerent stages during
the acquisition of trace conditioning in rabbits. MIF-1 also
facilitates passive avoidance retention and inhibits shock-
suppressed water intake, ﬁndings interpreted as contributing
to the processes of memory consolidation [12]. In elevated-
plus-maze tests, mice treated with Tyr-MIF-1 tend to spend
more time in the open arms compared with the control
group, suggesting the anxiolytic properties of this peptide
that shows structural homology with MIF-1 [43]. Training
induces c-Fos mRNA expression in the piriform cortex
and the neocortex of n-3-fatty acid depleted rats, who
showedlearningimprovementinanolfactorydiscrimination
task [44]. MIF-1 also improves the capacity of rats to
store information received through olfactory cues in social
investigatory behavior [45].
In summary, the results show that MIF-1 increased c-
Fos expression in brain regions involved in the regulation
of mood, anxiety, depression, and memory. Blood-borne
MIF-1 induced a greater extent of activation than that
after icv, suggesting a prominent role of blood-brain barrier
permeation. The activation status of pERK and pSTAT3 may
contribute to the overall expression level of c-Fos. Thus, the
results indicate the cellular mechanisms of actions of MIF-
1 that may underlie the therapeutic eﬀects of MIF-1 in the
treatment of Parkinson’s disease and depression.
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